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Abstract
To elucidate the proteomic features of aging in plasma, the subproteome targeted by the SOMAscan 
assay was profiled in blood samples from 202 females from the TwinsUK cohort.  Findings were 
replicated in 677 independent individuals from the AddNeuroMed, Alzheimer’s Research UK, and 
Dementia Case Registry cohorts.  Results were further validated using RNAseq data from whole blood 
in TwinsUK and the most significant proteins were tested for association with aging-related phenotypes 
after adjustment for age. Eleven proteins were associated with chronological age and were replicated 
at protein level in an independent population. These were further investigated at gene expression level 
in 384 females from the TwinsUK cohort. The two most strongly associated proteins were chordin-like 
protein 1 (meta-analysis β [SE] = 0.013 [0.001], p = 3.66 × 10−46) and pleiotrophin (0.012 [0.005], p = 3.88 × 
10−41). Chordin-like protein 1 was also significantly correlated with birthweight (0.06 [0.02], p = 0.005) and 
with the individual Framingham 10-years cardiovascular risk scores in TwinsUK (0.71 [0.18], p = 9.9 × 10−5). 
Pleiotrophin is a secreted growth factor with a plethora of functions in multiple tissues and known to be 
a marker for cardiovascular risk and osteoporosis. Our study highlights the importance of proteomics to 
identify some molecular mechanisms involved in human health and aging.
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Aging is a complex multifactorial process, which represents the accu-
mulation of molecular, cellular, and organ damage over time leading 
to loss of function and increased vulnerability to disease and death 
(1). A number of genetic and nongenetic factors, including lifestyle 
and environmental factors, contribute to human aging. The aging pro-
cess manifests probably due to a progressive accumulation of diverse 
adverse molecular changes resulting from a combination of environ-
mental, epigenetic, posttranslational, microbial, and lifestyle factors 
that increase the risk of death (2). It has been postulated that health 
outcomes during aging can be determined during early development 
(3). Observational and experimental evidence increasingly supports a 
relation between growth and development during fetal and infant life 
and health in later years, termed the developmental origins of health 
and disease (3). For example, an individual’s health status in middle 
and old age, and the risk of premature death due to cardiovascular 
or metabolic disease, is dependent on perinatal and early life traits 
such as birthweight (3). Identifying age biomarkers can help to pre-
dict and monitor age-related physiological decline and disease, and, 
importantly, it can also provide molecular insights into the aging pro-
cess and into early developmental processes that influence aging (4–7).
Metabolomic and glycomics analysis of blood samples have success-
fully been used to identify key molecular mechanisms underlying human 
health and aging (7,8). Additional molecular signatures of health and 
aging can be found using high-throughput proteomics. However, due 
to the high cost, this has been relatively understudied. Recently, three 
studies on aging using high-throughput proteomics identified proteins 
whose plasma levels (9,10) and cerebrospinal fluid (CSF) levels (11) 
substantially change with increasing age. However, these studies either 
did not apply a correction for multiple testing or did not validate their 
findings in independent cohorts. Proteomics profiling in the CSF study 
(11) was obtained using SOMAscan (12), a Slow Off-rate Modified 
Aptamer (SOMAmer)-based capture array. SOMAscan involves the 
use of SOMAmers (single-stranded DNA aptamers) to assay proteins in 
multiplex using DNA microarrays. As such, SOMAscan quantifies the 
level of the subproteome of proteins targeted by SOMAmers. A total of 
1,129 of these SOMAmers are currently available, and a third has been 
assessed for specificity using pull-down and mass spectrometry.
The SOMAscan approach has previously been used by us and 
others to study plasma proteins related to Alzheimer and related 
phenotypes (13–15).
In this study, we use the SOMAscan approach to assess the extent 
to which proteins are correlated with chronological age in a cohort 
of female twins with independent replication. We further investigate 
gene expression levels for those proteins that correlate with age 
using RNAseq data from whole blood in twins. Finally, we examine 
the association of specific proteins with factors relating to biologic 
aging such as birthweight and cardiovascular risk.
Methods
Study Populations
Study subjects were twins enrolled in the TwinsUK (TUK) registry, a 
national register of adult twins. Twins were recruited as volunteers 
by successive media campaigns without selecting for particular dis-
eases or traits (12). In this study, we analyzed data from 206 female 
twins who have SOMAscan protein data available.
Replication Cohort—AddNeuroMed, Alzheimer’s 
Research UK, and Dementia Case Registry
The replication cohort was drawn from a combination of 
AddNeuroMed (ANM) and the Alzheimer’s Research UK/Maudsley 
BRC Dementia Case (ARUK/DCR) Registry at King’s Health Partners 
Alzheimer’s Disease research cohorts (referred to collectively as 
ANM + ARUK + DCR) at King’s College London with SOMAscan 
data available as previously described (15). A total of 677 individu-
als (both males and females) were included in the analysis.
All samples and information were collected with written and 
signed informed consent. All studies were approved by the local 
research ethics committees.
Protein Measures and Quality Control
Proteins were measured using a SOMAmer-based capture array 
called “SOMAscan” (SomaLogic Inc, Boulder, CO). SOMAmers are 
single-stranded DNA aptamers, which include some bases that have 
been chemically modified to mimic protein side chains while retain-
ing the ability to base pair with standard DNA bases (allowing their 
levels to be quantified by PCR or microarrays). A total of 1,129 of 
these SOMAmers are currently available, and they can be used to 
analyze a biologic sample in such a way that the amount of each 
type of SOMAmer remaining in the sample is proportional to the 
amount of the corresponding protein targets in the original sample. 
Currently, a third of the SOMAmers have been assessed for speci-
ficity using pull-down and mass spectrometry. For more details on 
the approach, see Gold and colleagues (12), and the SomaLogic Inc 
Web site (http://www.somalogic.com/Products-Services/SOMAscan/
FAQs.aspx). TUK proteomic data were collected using SOMAscan 
v3, measuring 1,129 proteins, whereas ANM + ARUK + DCR pro-
teomic data were collected using SOMAscan v2, measuring 1,001 
proteins. All except 21 of the proteins measured by SOMAscan v2 
are also measured by SOMAscan v3. 
TUK proteomics data are publicly available upon request on the 
department website (http://www.twinsuk.ac.uk/data-access/access-
management/). We aim to make the ANM + ARUK + DCR data 
available to the public as soon as possible. In the short term, the 
authors can be contacted and collaborations established under an 
agreement shared with SomaLogic.
Quality control was performed at the sample and SOMAmer level, 
and involved the use of control SOMAmers on the microarray and 
calibration samples. At the sample level, hybridization controls on the 
microarray were used to monitor sample-by-sample variability in hybrid-
ization, while the median signal over all SOMAmers was used to moni-
tor overall technical variability. The resulting hybridization scale factor 
and median scale factor were used to normalize data across samples.
RNAseq
Whole blood samples from 384 female twins were prepared for 
sequencing and processed as previously described (16). Briefly, sam-
ples were prepared for sequencing with the Illumina TruSeq sample 
preparation kit (Illumina, San Diego, CA) according to manufac-
turer’s instructions and were sequenced on a HiSeq2000 machine. 
Then, the 49-bp sequenced paired-end reads were mapped to the 
GRCh37 reference genome. 
Statistical Analysis 
Statistical analysis of the protein data was carried out using Stata 
version 11/12.
Step 1. Data quality control
We log10 transformed the protein data as the protein concentrations 
were not normally distributed. Additionally, protein values ± 6 SDs 
were excluded as outliers.
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Step 2. Identify proteins associated with chronological age
In the TUK data, we looked for proteins associated with chronologi-
cal age by running random intercept linear regression adjusting for 
family relatedness:
  
 
E X ageij i ij j ij( )= + + +β β ζ ε0 ,  (1)
where Xij is the protein residual of twin j from pair i; ζj is the family-
specific error component, which represents the omitted family char-
acteristics or unobserved heterogeneity. We corrected for multiple 
comparisons using Bonferroni correction thus giving a significant 
threshold (p = .05/(1,129 proteins) = 4.43 × 10–5).
Step 3. Replication in the ANM + ARUK + DCR sample of 
significant proteins
We replicated our significant findings in the ANM + ARUK + DCR 
data running linear regressions adjusting for sex and recruitment 
centre. We combined discovery and validation results using an 
inverse variance Han and Eskin random effect meta-analysis (17).
Step 4. Influence of expression on age-related proteins (TUK)
Rank normalized reads per exon were used to assess the age effect on exon 
expression. A linear mixed model was fitted to examine age effect on gene 
expression in R (http://www.r-project.org/) with the lmer function in the 
lme4 package (18). Confounding factors in the models included as fixed 
effects were primer insert size, GC content mean, and batch. Random 
effect confounding factors included primer index, date, family relation-
ship, and zygosity. The p values to assess significance for age effect were 
calculated from the Chi-square distribution with 1 degree of freedom 
using likelihood ratio as the test statistic, while comparing a null model 
(expression ~ fixed covariates + random covariates) versus a full model 
with age (expression ~ age + fixed covariates + random covariates).
Step 5. Heritability of age-related proteins in TUK
We estimated heritability using structural equation modeling to separate 
the observed phenotypic variance into three latent sources of variation: 
additive genetic variance (A), shared/common environmental variance 
(C), and nonshared/unique environmental variance (E) (19). Heritability 
is defined as the proportion of the phenotypic variation attributable to 
genetic factors and is given by the equation, h2 = (A)/(A+ C + E).
Step 6. Identify a proteomics panel of independent proteins 
associated with chronological age (TUK)
Although the hypothesis underlying our work is that protein levels 
change with age, in order to investigate which proteins are correlated 
independently of each other with age we carried out a backward lin-
ear regression in the TUK data, with age as the dependent variable. 
This was performed on a total of 11 proteins, identified in Step 2 
and replicated at protein level (Step 3) or with consistent association 
with age at gene expression level (Step 4). We used p = .01 as a cutoff 
for the removal of variables from the model.
Step 7. Assess whether the protein panel associated with 
chronological age is also associated with known markers of 
early development and cardiovascular risk (TUK)
To determine whether the identified proteins are also markers of 
early development, we examined the association of the age-associ-
ated proteins and birthweight in twins, by running random intercept 
linear regression adjusting for age and family relatedness.
Finally, we explored the association of selected proteins with the 
Framingham 10-years cardiovascular risk (20) in twins.
Results
The demographic characteristics of the study populations are pre-
sented in Table 1 and Supplementary Table S1. Age was found to 
correlate in TUK with 13 proteins after accounting for multiple test-
ing (p < 4.4 × 10–5) and family relatedness (Table 2). Of these pro-
teins, 10 were also found to associate with age in the independent 
ANM + ARUK + DCR cohort after adjusting for sex and recruitment 
centre (Table 2). Stratifying ANM + ARUK + DCR by gender and/or 
diagnosis did not change the results (data not shown).
We further tested in 384 females (age range 39–83 years) from 
TUK the association of whole blood gene expression of the genes 
encoding all 13 proteins and found three of them (CST3, FSTL3, 
and HAVCR2) to be nominally significant (Supplementary Table S2). 
This gives a total of 11 proteins replicated at protein level or with 
consistent association with age at gene expression level (CHRDL1, 
CCDC80, PTN, ROR1, CST3, FSTL3, HAVCR2, IGFBP6, MMP12, 
TIMP1, and THBS4).
Of the 11 proteins, the circulating levels of four of them—namely 
PTN, ROR1, TIMP1, and CST3—had already shown to associate 
with age in CSF levels (all but PTN in the same direction as in this 
study) (11). A hypergeometric test revealed that this overlap is sig-
nificant at the .05 level (overlapping population size = 831, number 
of CSF levels protein markers associated with age = 81, number of 
replicated blood marker associated with age = 11, overlapping mark-
ers = 4, p = .018).
Taking advantage of the twin nature of our data, we ran a her-
itability analysis (19) for each of the 11 replicated proteins. The 
calculated heritabilities ranged from 0% to 63% (Table 2) with cir-
culating levels of 9 of the 11 replicated proteins having a genetic 
contribution of 31% or less.
In the TUK data, a backward linear regression including the 11 
replicated proteins revealed 4 proteins—PTN, CHRDL1, MMP12, 
and IGFP6—to be independently associated with age. It has been 
extensively shown that low birth weight is associated with increased 
rates of coronary heart disease, stroke, type 2 diabetes adiposity, the 
metabolic syndrome, and osteoporosis in adult life (3). We there-
fore investigated whether any of the four proteins are associated 
with birthweight, a marker of early development, and found that 
birthweight is significantly associated with CHRDL1 (β = 0.06, SE = 
0.02, p = .005) after adjusting for age. Circulating levels of CHDRL1 
are also significantly associated with the Framingham cardiovascular 
disease 10-years risk score calculated for TUK subjects after adjust-
ing for age (−0.71 [−1.06; −0.36], p = 9.9 × 10−5), thus suggesting that 
there is a relationship between early development and age-related 
Table 1. Demographic Characteristic of the Discovery and Replica-
tion Populations 
Phenotype TUK ANM + ARUK + DCR
N 206 677
Females, N (%) 206 (100%) 420 (62%)
MZ:DZ: Singletons 114:86:6 0:0:677
Age, y, mean (SD) 65.30 (6.92) 76.96 (7.06)
Note: ANM  =  AddNeuroMed; ARUK  =  Alzheimer’s Research UK; 
DCR = Maudsley BRC Dementia Case; TUK = TwinsUK; MZ = monozygotic; 
DZ = dizygotic. 
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health deterioration. Moreover, circulating levels of CHRDL1 are 
significantly associated with many biologic aging markers (diastolic 
blood pressure, dehydroepiandrosterone sulfate, force expiratory 
volume in one second, force vital capacity, high-density lipoprotein 
cholesterol, insulin resistance, and especially waist hip ratio and tri-
glycerides (Table 3) after adjusting for age. Thus, although CHRDL1 
levels increase with age, higher levels are actually correlated with 
lower cardiovascular risk and with higher weight at birth (which 
generally predicts better health outcomes in later age). This rela-
tionship was further confirmed when we computed the difference 
in Framingham cardiovascular disease risk between pairs of twins 
and the difference in CHDRL1 levels. We find a strong significant 
negative correlation between the two: the difference between twins 
in a pair in CHDRL1 levels is negatively correlated with the differ-
ence in Framingham cardiovascular disease risk (β = −0.002, SE = 
0.001, p = .003).
None of the remaining three proteins associate with birthweight. 
However, MMP12 nominally associates with high-density lipopro-
tein cholesterol, while IGF6 correlates with dehydroepiandrosterone 
sulfate, estimated glomerular filtration rate, total cholesterol, and 
C-glycosyl tryptophan, a previously identified metabolite marker of 
aging (8) (Table 3).
For each TUK study participant, we then generated a linear com-
bination of the key four proteins using the regression coefficients and 
created a protein-derived age variable. Plotting this variable in our 
samples shows a clear relationship with age (Figure 1a) and high-
lights that the greatest differences in protein-derived age arise later 
on in life (ie, over the age of 68). For each ANM + ARUK + DCR 
subject, we calculated the same protein-derived age variable (model 
parameters determined from model fitting to TUK data), this is plot-
ted in Figure 1b, showing again a clear relationship with age.
Discussion
This is the first study to use the high-throughput SOMAscan pro-
teomics approach to study age-related changes in protein plasma 
levels. We identified 11 proteins whose levels significantly increase 
with increasing age and that replicated in an independent cohort at 
protein level or had consistent association with age at gene expres-
sion level, highlighting the robustness of our results. Many of these 
proteins have been previously associated with age in a CSF proteins 
study (11). Most of these proteins have a very low heritability, con-
sistent with published reports that indicate that human aging and 
longevity have only a modest genetic contribution and a strong 
Table 2. List of Proteins Significantly Associated With Age in the Discovery Cohort and Replication Cohort 
Protein UniProt Gene h2 [95% CI] in 
TUK
TUK ANM + ARUK + DCR RE Han and Eskin Meta-
analysis
β (SE) p β (SE) p β (SE) p
Chordin-like protein 
1
Q9BU40 CHRDL1 0.1 [0, 0.63] 0.014 (0.002) 2.3 × 10−12 0.012 (0.001) 1.9 × 10−33 0.013 (0.001) 3.66 × 10−46
Coiled-coil domain- 
containing protein 
80
Q76M96 CCDC80 0.31 [0, 0.71] 0.015 (0.002) 1.7 × 10−9 0.007 (0.001) 5.1 × 10−29 0.011 (0.004) 2.55 × 10−43
Pleiotrophin P21246 PTN 0.52 [0, 0.67] 0.018 (0.002) 3.6 × 10−15 0.007 (0.001) 1.2 × 10−24 0.012 (0.005) 3.88 × 10−41
Follistatin-related 
protein 3*
O95633 FSTL3 0.22 [0, 0.71] 0.011 (0.002) 3.6 × 10−5 0.007 (0.0006) 3.1 × 10−32 0.008 (0.002) 8.23 × 10−38
Metalloproteinase 
inhibitor 1
P01033 TIMP1 0 [0, 0.54] 0.009 (0.002) 1.5 × 10−8 0.004 (0.0004) 4.4 × 10−23 0.006 (0.003) 6.74 × 10−30
Macrophage metal-
loelastase
P39900 MMP12 0.31 [0, 0.77] 0.027 (0.005) 1.6 × 10−7 0.004 (0.0004) 2.8 × 10−18 0.015 (0.011) 8.92 × 10−28
Cystatin-C* P01034 CST3 0.63 [0.12, 
0.74]
0.009 (0.002) 3.2 × 10−5 0.004 (0.0004) 5.6 × 10−26 0.006 (0.002) 2.68 × 10−27
Insulin-like growth 
factor-binding 
protein 6
P24592 IGFBP6 0.26 [0, 0.63] 0.01 (0.002) 1.2 × 10−6 0.004 (0.001) 9.9 × 10−13 0.007 (0.003) 3.10 × 10−16
Tyrosine-protein ki-
nase transmembrane 
receptor ROR1
Q01973 ROR1 0.18 [0, 0.36] 0.01 (0.002) 1.4 × 10−6 0.004 (0.001) 1.9 × 10−11 0.007 (0.003) 3.86 × 10−16
Thrombospondin-4 P35443 THBS4 0.24 [0, 0.55] 0.008 (0.002) 4.2 × 10−5 0.003 (0.001) 2.5 × 10−4 0.005 (0.003) 3.47 × 10−8
Hepatitis A virus 
cellular receptor 2*
Q8TDQ0 HAVCR2 0.24 [0, 0.61] 0.011 (0.003) 3.1 × 10−5 NA NA NA NA
A disintegrin and 
metalloproteinase 
with thrombospon-
din motifs 5
Q9UNA0 ADAMTS5 0.60 [0.30, 0.73]0.014 (0.003) 1.7 × 10−6 0.0004 
(0.0003)
0.21 — —
Tumor necrosis factor 
receptor superfamily 
member 27
Q9HAV5 EDA2R 0.17 [0, 0.61] 0.013 (0.002) 2.6 × 10−7 −0.0005 
(0.001)
0.25 — —
Notes: ANM = AddNeuroMed; ARUK = Alzheimer’s Research UK; DCR = Maudsley BRC Dementia Case; h2 = heritability; NA = not applicable; TUK = Twin-
sUK.
*Validated in gene expression data (see Supplementary Table S1). 
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environmental one (21). We also report a panel of four replicating 
proteins (PTN, CHRDL1, MMP12, and IGFP6) that are indepen-
dently associated with chronological age.
CHRDL1
The protein most associated with chronological age is CHRDL1, 
a bone morphogenetic protein-4 antagonist, which is involved in 
bone morphogenic protein signaling and regulation and signaling 
by GPCR (22). Plasma levels of CHRDL1 are strongly correlated (r 
= 0.60) with levels of CCDC80, the protein with the second highest 
p value (Table 2). CHRDL1 also plays a role in regulating retinal 
angiogenesis through modulation of bone morphogenic protein 4 
actions in endothelial cells and during anterior segment eye devel-
opment (23). In our study, CHRDL1 is of particular interest as it 
is not only associated with chronological age but also with birth-
weight, a factor affecting healthy aging and its levels have a very 
low heritability, with 90% of CHRDL1 levels being environmentally 
determined. The epidemiological observations that low birthweight 
is associated with increased rates of coronary heart disease, stroke, 
type 2 diabetes adiposity, the metabolic syndrome, and osteoporosis 
in adult life (24) have been extensively replicated. Here, we find that 
higher birthweight is significantly associated with higher circulating 
levels of CHDRL1 and that higher circulating levels of CHDRL1 are 
in turn associated with a lower cardiovascular disease risk. Thus, a 
positive linear correlation with regards to chronological age does not 
necessarily imply that the protein is functionally linked to any bio-
logic aging phenotype. Indeed, we find that CHRDL1 increases with 
age, but decreases for most of the markers of increased physiological 
deterioration (Table 3).
PTN
PTN is a secreted growth factor composed of 168 amino acid resi-
dues. The name pleiotrophin is widely accepted nowadays and reflects 
the plethora of functions it exerts in different tissues and cell lines. 
Two SNPs (rs322236 and rs3959914) within the first intron of the 
gene encoding PTN have been associated with volumetric bone mass 
Table 3. Association of Proteins Independently Associated With Age in TwinsUK and Age-Related Phenotypes After Adjusting for Chrono-
logical Age (p < .05) 
Protein UniProt Gene Phenotype β SE p
Chordin-like protein 1 Q9BU40 CHRDL1 Birthweight 0.06 0.02 .005
CVD risk 
(Framingham)
−0.71 0.18 9.9 × 10−5
DBP −0.004 0.001 .004
DHEAS −0.02 0.01 .03
FEV1 0.08 0.03 .01
FVC 0.07 0.03 .007
HDL cholesterol 0.11 0.04 .004
HOMA −0.04 0.01 .004
Triglycerides −0.13 0.03 1.19 × 10−5
WHR −0.83 0.20 9.93 × 10−5
Insulin-like growth factor- 
binding protein 6
P24592 IGFBP6 C-GlyTrp 0.08 0.02 1.33 × 10−5
DHEAS −0.02 0.01 .04
eGFR −0.004 0.001 .01
Total cholesterol −0.04 0.02 .02
Macrophage metalloelastase P39900 MMP12 HDL cholesterol −0.11 0.05 .04
Note: CVD risk = cardiovascular disease risk, DBP = diastolic blood pressure; DHEAS = dehydroepiandrosterone sulfate; eGFR = estimated glomerular filtration 
rate; FEV1 = forced expiratory volume in 1 second; FVC = force vital capacity; HDL = high-density lipoprotein; HOMA = homeostatic model assessment (insulin 
resistance); WHR = waist hip ratio.
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Figure 1.  Protein measure and age. (a) The protein measure was calculated from each TwinsUK (TUK) participant using the coefficients from the backward 
regression on age of the 11 proteins in Table 2. (b) These coefficients and blood proteins were also used to calculate a protein measure of aging in the combined 
ANM + ARUK + DCR cohort. 
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density (25). Polymorphisms in the PTN gene promoter have been 
also mentioned to affect bone density and might be implicated in 
osteoporosis (26). PTN acts via various receptors (reviewed in (27)), 
like the receptor protein tyrosine phosphatase β/ζ ανβ3integrin, 
nucleolin, N-syndecan, and anaplastic lymphoma kinase.
Mice deficient in both PTN and midkine have high mortality 
rates within a month of their birth (28) and exhibit female infer-
tility (28). PTN-overexpressing mice exhibit abnormalities in bone 
formation (29–31) PTN expression has been reported in vascular-
ized human atherosclerotic plaques (32) and has been also suggested 
as a diagnostic marker and a therapeutic target for heart failure 
(reviewed in (33)). In our study, we do not find PTN associated with 
markers of biologic aging, but this may be due to the reduced sample 
size of the study sample.
IGFBP-6
Insulin-like growth factor-binding protein-6 (IGFBP-6) is a secreted 
glycoprotein that reduces the bioavailability of IGFs in particular 
IGF-II (34). It has both IGF-dependent and -independent effects on 
cell growth. IGFBP-6 can be internalized and translocated to the 
nucleus and interacts with the vitamin D receptor (35) and thyroid 
hormone receptor α1 (36). Although we find that IGFBP-6 levels 
increase with age, in vitro results show that downregulation of 
IGFBP-6 led to premature entry into cellular senescence and that 
IGFBP-6 over expression increases cellular life span (37). The pleio-
tropic effects of IGFBP-6 effects are confirmed in the clinical data 
from the TUK cohort: on the one hand, its levels are negatively cor-
related with dehydroepiandrosterone sulfate and estimated glomeru-
lar filtration rate both of which are known to decline with age. On 
the other hand, circulating levels of IGFBP-6 are also correlated with 
lower total cholesterol, which normally increases with age and is a 
marker of higher cardiovascular risk.
MMP-12
Matrix metalloproteinase-12 (MMP-12) has been strongly impli-
cated in the aging process in several tissues, such as lung, skin, and 
brain. For example, tropoelastin and fibrillin degradation in skin 
by MMP-12 has been implicated in the accumulation of elastotic 
material in photoaged skin (38). During aging, the brain displays 
an increased proinflammatory status, which is associated with the 
pathogenesis of aging-related diseases such as Alzheimer’s and 
Parkinson diseases. MMPs facilitate the migration of inflamma-
tory cells in tissues and modulate their inflammatory activity. In 
particular, upregulated cerebral MMP-12 during aging enhances 
aging-associated neuroinflammation by facilitating recruitment of 
bone marrow-derived microglia into the brain (39). Emphysema-like 
change in mice due to increasing age has been shown to be facilitated 
by increased MMP-12 expression that accelerates elastin degrada-
tion in mice lungs (40). Moreover, MMP-12 was listed as one of the 
10 novel proteins for cardiovascular risk stratification (hazard ratio 
= 3.45 between the highest and lowest quintiles for all subsequent 
cardiovascular events) in over 900 individuals with a median 6-years 
follow-up period from the Heart and Soul study (41).
It has been widely reported that, in humans and other organ-
isms, the correlations between gene expression and protein levels are 
not very high (~40%). Current data demonstrate a substantial role 
for regulatory processes occurring after messenger RNA (mRNA) 
is made—that is, posttranscriptional, translational, and protein 
degradation regulation—in controlling steady-state protein abun-
dances (42). For the four proteins that we report here as consistently 
and independently associated with age—namely CHRDL1, PTN, 
IGFBP6, and MMP12—we find that the relationship with age is the 
same both for mRNA and protein levels, although it is not significant 
with mRNA. There are many processes between transcription and 
translation, which result in a weak correlation between protein levels 
and mRNA levels and protein stability is a big factor. The fact, how-
ever, that the relationship with chronological age remains suggests 
that the increased levels of these proteins with increasing age is not a 
result of an accumulation of the protein or a lack of degradation, but 
can be, at least to a certain extent, be attributed to gene expression 
and thus to a direct regulation of their levels.
We note some limitations to this study. Our discovery sample is 
small and consisted of middle-aged women only. We only studied 
the subproteome quantifiable using SOMAscan, it is therefore likely 
that there are many age-related proteins that were not measured by 
this study. There is no overlap in the blood proteins identified to be 
significantly associated with aging in this and the two previous dis-
covery studies (9,10). This may be due to the difference in proteomic 
approaches or the lack of multiple testing corrections used in the previ-
ous studies. In comparison, a study that looked at CSF proteins using 
the same proteomic approach and multiple testing corrections had a 
significantly overlapping set of markers of aging (11). The ability of 
these proteins to cross the blood–brain barrier is unknown, so it is not 
known whether this signal crosses between CSF and blood, or whether 
the same aging process affects their levels independently. PTN is associ-
ated with age in a different direction in this study in comparison than 
in the CSF study (11), this may be due to cohort heterogeneity or tissue-
specific differences. Of the 11 proteins associated with age, only three 
show changes in expression in the corresponding coding genes. The 
first most likely reason for the lack of correlation between expression 
and protein levels are the different methods resolution and samples 
sizes. The sensibilities of the different techniques to identify changes 
with ages were different but also the ages ranges of both sets are dif-
ferent. Moreover, it has been shown that the levels of transcription are 
not strong predictors for protein levels due to transcriptional noise 
and posttranscriptional modifications as well as the higher stability of 
proteins compare with mRNAs (42). Finally, specificity experiments 
by pull-down mass spectrometry have been performed on a third of 
the 1,129 proteins on the menu, so some of the proteins we analyzed 
may have extra noise due to nonspecific binding. However, this is the 
case for any affinity-based protein assay, including more standard 
approaches, for example, antibody based. Also, SOMAscan has been 
shown to be a very robust technology in previous studies (43).
In conclusion, our study highlights the potential of proteomic 
approaches for identifying molecular pathways related to aging. At 
the same time, these data also illustrate some of the challenges in 
aging research and in particular with regards to the interpretation of 
omics data with regards to the role of specific molecules with regards 
to aging. CHRDL1 is the most strongly associated with age, with 
levels increasing in older individuals. However, higher levels are also 
correlated with lower predicted cardiovascular risk and higher birth-
weight (a determinant of healthier aging). Therefore, these results 
need to be interpreted with caution and suggest that longitudinal 
studies are needed to understand the role of some of these molecules 
in the aging process.
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